Evaluating products.

The dosing pattern the entire berberine literature was built on: 500 mg two to three times daily with meals — the regimen of the landmark diabetes trials and the pooled analyses (HbA1c reductions of roughly 0.6–1.0%, meaningful LDL and triglyceride improvements, modest weight effects). Honest boundaries stated once, clearly: the trials are small, short, and marker-based — no UKPDS-class outcome data exists, and 'nature's metformin' describes a mechanism neighborhood, not an evidence class. 🚨 The interaction set is real pharmacology: berberine inhibits CYP2D6, CYP2C9, and CYP3A4 and the P-glycoprotein efflux pump — anyone on ANY prescription medication (especially glucose-lowering drugs: additive hypoglycemia risk; cyclosporine and CYP-metabolized drugs: level-raising) involves their physician before the first capsule. Absolutely avoided in pregnancy and while nursing newborns (uterotonic activity, placental transfer, and the neonatal kernicterus risk from bilirubin displacement). GI effects — constipation, cramping, loose stools in a meaningful minority — are dose-limiting: start at 500 mg once daily with a meal, and titrate up over a week.